Literature DB >> 30693054

Hemodynamics of cardiac tamponade during extracorporeal membrane oxygenation support in a patient with fulminant myocarditis.

Toru Kondo1, Ryota Morimoto1, Tsuyoshi Yokoi1, Shogo Yamaguchi1, Tasuku Kuwayama1, Tomoaki Haga1, Hiroaki Hiraiwa1, Yuki Sugiura1, Naoki Watanabe1, Naoaki Kano1, Takeo Ichii1, Kenji Fukaya1, Akinori Sawamura1, Takahiro Okumura1, Tomo Yoshizumi2, Masato Mutsuga2, Kazuro Fujimoto2, Naoyuki Matsuda3, Akihiko Usui2, Toyoaki Murohara1.   

Abstract

Fulminant myocarditis (FM) causes rapid onset severe heart failure requiring inotropes or mechanical circulatory support. Myocarditis is sometimes associated with pericardial effusion, however, how this effusion affects the hemodynamics in patients with FM under venoarterial extracorporeal membrane oxygenation (VA-ECMO) management has not been fully reported. We show a case of FM presenting with cardiac tamponade during VA-ECMO management. A 64-year-old female diagnosed as having FM showed a rapid hemodynamic collapse and that led to the application of VA-ECMO. Although her left ventricular ejection fraction did not improve despite proper hemodynamics management for several days, a pericardial effusion accumulated gradually. Apparent elevation of right atrial pressure and reduction of blood pressure were not observed, however, we performed pericardiocentesis because we were not able to wean off VA-ECMO. After the drainage of pericardial effusion, the blood pressure and cardiac output elevated as did the left ventricular ejection fraction. We successfully removed VA-ECMO and the patient was discharged without any complications. This is a case report in which a cardiac tamponade under VA-ECMO did not show typical signs and pericardiocentesis contributed to withdrawal of a VA-ECMO system. <Learning objective: Typical findings of cardiac tamponade are less likely to appear in patients with fulminant myocarditis under venoarterial extracorporeal membrane oxygenation management (VA-ECMO). Drainage of pericardial effusion delivers dramatic improvement in blood pressure, cardiac output, and left ventricular ejection fraction. When VA-ECMO cannot be weaned off, pericardiocentesis should be considered in patients with fulminant myocarditis who showed gradual accumulation of pericardial effusion.>.

Entities:  

Keywords:  Cardiac tamponade; Extracorporeal membrane oxygenation; Myocarditis

Year:  2018        PMID: 30693054      PMCID: PMC6342684          DOI: 10.1016/j.jccase.2018.08.009

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  5 in total

Review 1.  Acute cardiac tamponade.

Authors:  David H Spodick
Journal:  N Engl J Med       Date:  2003-08-14       Impact factor: 91.245

Review 2.  Pathophysiology of cardiac tamponade.

Authors:  D H Spodick
Journal:  Chest       Date:  1998-05       Impact factor: 9.410

3.  Survival and Left Ventricular Function Changes in Fulminant Versus Nonfulminant Acute Myocarditis.

Authors:  Enrico Ammirati; Manlio Cipriani; Marzia Lilliu; Paola Sormani; Marisa Varrenti; Claudia Raineri; Duccio Petrella; Andrea Garascia; Patrizia Pedrotti; Alberto Roghi; Edgardo Bonacina; Antonella Moreo; Maurizio Bottiroli; Maria P Gagliardone; Michele Mondino; Stefano Ghio; Rossana Totaro; Fabio M Turazza; Claudio F Russo; Fabrizio Oliva; Paolo G Camici; Maria Frigerio
Journal:  Circulation       Date:  2017-06-02       Impact factor: 29.690

4.  Cardiac tamponade: hemodynamic observations in man.

Authors:  P S Reddy; E I Curtiss; J D O'Toole; J A Shaver
Journal:  Circulation       Date:  1978-08       Impact factor: 29.690

Review 5.  Myopericarditis: Etiology, management, and prognosis.

Authors:  Massimo Imazio; Rita Trinchero
Journal:  Int J Cardiol       Date:  2008-01-24       Impact factor: 4.164

  5 in total
  1 in total

Review 1.  The ABCDE approach to difficult weaning from venoarterial extracorporeal membrane oxygenation.

Authors:  Christiaan L Meuwese; Daniel Brodie; Dirk W Donker
Journal:  Crit Care       Date:  2022-07-15       Impact factor: 19.334

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.